top of page
CHIUMERIC 12.png

ASX:CHM

Announcements

ASX:CHM

Annual Reports

ASX:CHM

Investor Presentations

CHIMERIC

Media

CHIMERIC

Articles

01.06.2026

Chimeric CAR T therapy delivers durable disease control in early GI cancer trial

Biotech Dispatch

25.02.2026

Investor Guide: Health & Biotech 2026 featuring Tim Boreham

Stockhead

17.02.2026

Chimeric Therapeutics names experienced biotech leader as chair in board and executive refresh

Biotech Dispatch

12.02.2026

Chimeric escalates CDH17 CAR-T trial to highest dose after strong safety and early activity signals

Biotech Dispatch

17.11.2025

The Australian biotechs racing toward the next billion-dollar cancer drug

Forbes

13.11.2025

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

Biotech Dispatch

CHIMERIC

Corporate Governance

Corporate Governance Statement

Online Meeting Guide

Anti-Bribery & Corruption Policy

Audit & Risk Committee Charter

Board Charter

Code of Conduct

Communication & Disclosure Policy

Privacy Policy

Remuneration & Nomination Committee Charter

Risk Management Policy

Securities Trading Policy

Whistleblower Policy

Diversity Policy

Constitution

CHIMERIC

Important Information

CHIMERIC 03.png

Want to know more?

Chimeric Therapeutics is focused upon delivering results for patients, partners and investors.

bottom of page